Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C-646 is a selective, small-molecule inhibitor of the lysine acetyltransferases p300 and CBP (CREB-binding protein). It functions as a competitive inhibitor of acetyl-CoA binding to the p300 catalytic domain, thereby reducing the acetylation of histones and other non-histone proteins. In preclinical research, C-646 has been investigated for its potential to overcome resistance to Bruton's tyrosine kinase (BTK) inhibitors in mantle cell lymphoma (MCL) by suppressing NFκB activity and AKT phosphorylation. While widely utilized as a chemical probe to study epigenetic regulation and gene expression in various cancers, C-646 is primarily a research-use-only tool and has not advanced into clinical development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on C-646.